Progress of hematopoietic stem cell transplantation in treatment of peripheral T-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 185-189, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-929756
ABSTRACT
Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous rare malignant lymphoproliferative diseases, and PTCL patients have low therapeutic efficacy rate and poor prognosis after conventional comprehensive treatments. Hematopoietic stem cell transplantation (HSCT) can improve the survival of PTCL patients, and previous studies showed that patients with a definite diagnosis should receive high-dose chemotherapy combined with autologous-HSCT (auto-HSCT) in the first remission. In recent years, a consensus on the role of auto-HSCT as the first-line consolidation therapy for PTCL patients has not been reached so far. Allogeneic-HSCT is an effective option for relapsed and refractory patients with PTCL, while auto-HSCT has unfavorable efficacies. This paper reviews the research progress of HSCT in treatment of PTCL.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS